# LIVEOME

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liveome

- Industry: Biotechnology
- Headquarters: Suwon, South Korea
- Website: www.liveome.co.kr
- Total disclosed funding: $5.6M
- Latest round: Series A (Apr 25, 2022)
- Investors on record: 1

## About

Based in Suwon, South Korea, and founded in 2021, LIVEOME, a subsidiary of the biopharmaceutical company Medy-Tox Inc., operates as a health technology company that offers various technological solutions for drug development and various therapies. In April 2022, LIVEOME raised KRW 7 billion in series A funding from new investor Lindeman Asia. As of 2022, the company is led by Jiyoon Song.

The company offers microorganism-based technology used for various health therapies. The company also provides a drug development platform, drug dual platform technology, and solutions for various medical needs using genetic manipulation.

The company plans to use the April 2022 funding for the research and development of its pipeline and its global expansion.

## Funding rounds

- Series A, Apr 25, 2022, $5.6M — Lindeman Asia Investment

## Investors

- Lindeman Asia Investment (https://capitalatlas.ai/funds/lindeman-asia-investment) — Series A